AU2012343020B2 - Polyethylene glycol-modified integrin blocker HM-3 and use thereof - Google Patents

Polyethylene glycol-modified integrin blocker HM-3 and use thereof Download PDF

Info

Publication number
AU2012343020B2
AU2012343020B2 AU2012343020A AU2012343020A AU2012343020B2 AU 2012343020 B2 AU2012343020 B2 AU 2012343020B2 AU 2012343020 A AU2012343020 A AU 2012343020A AU 2012343020 A AU2012343020 A AU 2012343020A AU 2012343020 B2 AU2012343020 B2 AU 2012343020B2
Authority
AU
Australia
Prior art keywords
tumor
once
mpeg
human
nude mice
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2012343020A
Other languages
English (en)
Other versions
AU2012343020A1 (en
Inventor
Haimin CHANG
Zhian KANG
Hanmei Xu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU2012343020A1 publication Critical patent/AU2012343020A1/en
Application granted granted Critical
Publication of AU2012343020B2 publication Critical patent/AU2012343020B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/04—Peptides being immobilised on, or in, an organic carrier entrapped within the carrier, e.g. gel, hollow fibre
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU2012343020A 2011-11-21 2012-11-17 Polyethylene glycol-modified integrin blocker HM-3 and use thereof Active AU2012343020B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2011103705299A CN102417540A (zh) 2011-11-21 2011-11-21 一种聚乙二醇修饰的整合素阻断剂hm-3及其应用
CN201110370529.9 2011-11-21
PCT/CN2012/084788 WO2013075600A1 (zh) 2011-11-21 2012-11-17 一种聚乙二醇修饰的整合素阻断剂hm-3及其应用

Publications (2)

Publication Number Publication Date
AU2012343020A1 AU2012343020A1 (en) 2014-06-12
AU2012343020B2 true AU2012343020B2 (en) 2016-05-19

Family

ID=45942198

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012343020A Active AU2012343020B2 (en) 2011-11-21 2012-11-17 Polyethylene glycol-modified integrin blocker HM-3 and use thereof

Country Status (7)

Country Link
US (2) US20140329759A1 (enExample)
EP (1) EP2784093B1 (enExample)
KR (2) KR102106485B1 (enExample)
CN (1) CN102417540A (enExample)
AU (1) AU2012343020B2 (enExample)
IN (1) IN2014CN04482A (enExample)
WO (1) WO2013075600A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102417540A (zh) * 2011-11-21 2012-04-18 中国药科大学 一种聚乙二醇修饰的整合素阻断剂hm-3及其应用
CN103656615B (zh) * 2013-12-11 2017-01-04 南京安吉生物科技有限公司 一种hm-3和铂类、紫杉醇类或他滨类药物在制备实体瘤药物中的用途
CN103623394A (zh) * 2013-12-11 2014-03-12 南京安吉生物科技有限公司 一种peg-hm-3和铂类、紫杉醇类或他滨类药物在制备实体瘤药物中的用途
CN103739671B (zh) * 2013-12-31 2015-08-26 郭向华 一种聚乙二醇修饰的抑制核因子-κB多肽及其应用
CN103739673B (zh) * 2013-12-31 2015-08-19 浙江元太生物科技有限公司 一种聚乙二醇修饰的抑制白介素-6多肽及其应用
CN103739669B (zh) * 2013-12-31 2015-08-26 浙江元太生物科技有限公司 一种抑制白介素-6多肽及其应用
CN103736078B (zh) * 2014-01-09 2017-12-12 南京安吉生物科技有限公司 mPEG‑HM‑3多肽冻干粉针制剂及其制备方法和用途
CN103720667B (zh) * 2014-01-09 2016-04-13 中国药科大学 Ap-25多肽冻干粉针制剂及其制备方法和用途
CN103819542A (zh) * 2014-02-28 2014-05-28 中国药科大学 一种聚乙二醇修饰及蛋白质融合表达的整合素阻断剂ap-25及其应用
CN104127378A (zh) * 2014-08-11 2014-11-05 中国药科大学 mPEG-SC20K-HM-3多肽注射液及其制备方法和用途
CN105622721A (zh) * 2015-12-16 2016-06-01 李斯文 一种聚乙二醇修饰的血管生成抑制剂hs-1及其应用
CN105646667A (zh) * 2016-04-06 2016-06-08 南京安吉生物科技有限公司 聚乙二醇修饰的血管生成抑制剂hm-1及其应用
CN108623693B (zh) * 2017-03-20 2022-03-25 徐寒梅 一种融合蛋白及其制备方法和其在制备治疗眼科疾病、抗炎、抗肿瘤药物中的应用
CN109503700A (zh) * 2017-09-14 2019-03-22 南京安吉生物科技有限公司 马来酰亚胺基团修饰的血管生成抑制剂hm-1及其应用
CN107857800B (zh) * 2017-11-09 2020-05-05 北京赛升药业股份有限公司 一种长效整合素抑制剂及其应用
CN109879969B (zh) 2017-12-06 2024-04-09 天士力生物医药股份有限公司 一种hm-3融合蛋白及其应用
CN111855876B (zh) * 2020-07-10 2023-05-02 北京赛升药业股份有限公司 一种安替安吉肽有关物质的检测方法
CN113488512A (zh) * 2021-06-23 2021-10-08 深圳市华星光电半导体显示技术有限公司 显示面板及其制备方法
CN114230676B (zh) * 2021-12-22 2024-06-11 天士力生物医药股份有限公司 重组hm-3融合蛋白及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102145161A (zh) * 2011-04-07 2011-08-10 中国药科大学 整合素阻断剂在制备治疗肿瘤药物中的应用
CN102205110A (zh) * 2011-05-18 2011-10-05 中国药科大学 整合素阻断剂在制备治疗新生血管性眼病药物中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US6521593B1 (en) * 1999-02-01 2003-02-18 Childrens Hospital Los Angeles Methods for inhibiting brain tumor growth
MXPA05005469A (es) * 2002-11-25 2005-09-08 Attenuon Llc Peptidos que inhibien angiogenesis, migracion celular, invasion celular y proliferacion celular, composiciones y usos de los mismos.
CN1314705C (zh) * 2005-06-03 2007-05-09 中国药科大学 高效抑制血管生成多肽及其制备方法和应用
KR100863060B1 (ko) * 2006-06-02 2008-10-10 베이징 선바이오 바이오테크, 코오퍼레이션, 리미티드 암 억제 활동을 하는 재조합 단백질, 그 암호화 유전자 및 재조합 단백질을 활성성분으로 포함하는 암치료용 약학적 조성물
CN102178656B (zh) * 2011-05-12 2012-08-22 内蒙古奇特生物高科技（集团）有限公司 Hm-3多肽冻干粉制剂及其制备方法
CN102417540A (zh) * 2011-11-21 2012-04-18 中国药科大学 一种聚乙二醇修饰的整合素阻断剂hm-3及其应用
CN104127378A (zh) * 2014-08-11 2014-11-05 中国药科大学 mPEG-SC20K-HM-3多肽注射液及其制备方法和用途

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102145161A (zh) * 2011-04-07 2011-08-10 中国药科大学 整合素阻断剂在制备治疗肿瘤药物中的应用
CN102205110A (zh) * 2011-05-18 2011-10-05 中国药科大学 整合素阻断剂在制备治疗新生血管性眼病药物中的应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LIU Z, et al., Int J Mol Sci, (19 April 2011) Vol 12, pp2650-2663. *

Also Published As

Publication number Publication date
KR20140096373A (ko) 2014-08-05
US20170100489A1 (en) 2017-04-13
KR102106485B1 (ko) 2020-05-04
EP2784093A1 (en) 2014-10-01
AU2012343020A1 (en) 2014-06-12
WO2013075600A1 (zh) 2013-05-30
KR20190090872A (ko) 2019-08-02
EP2784093B1 (en) 2019-10-09
IN2014CN04482A (enExample) 2015-09-04
US20140329759A1 (en) 2014-11-06
EP2784093A4 (en) 2015-08-05
CN102417540A (zh) 2012-04-18

Similar Documents

Publication Publication Date Title
AU2012343020B2 (en) Polyethylene glycol-modified integrin blocker HM-3 and use thereof
AU2020401160B2 (en) Pharmaceutical TACI-Fc fusion protein formulation
CN112386678B (zh) 多肽或其衍生物的应用
Yin et al. Tumor targeting and microenvironment-responsive multifunctional fusion protein for pro-apoptotic peptide delivery
US12077566B2 (en) Mutants of recombinant immunoregulatory protein of Ganoderma lucidum and applications thereof
McMullen et al. A low-immunogenic genetically-fusible zwitterionic polypeptide
KR102003422B1 (ko) 인테그린 차단제 폴리펩타이드 및 그의 응용
AU2015305299A1 (en) Disintegrin variants and pharmaceutical uses thereof
US20170319648A1 (en) High activity tumour inhibitor and preparation method and use thereof
Shen et al. Benzyl stapled modification and anticancer activity of antimicrobial peptide A4K14-Citropin 1.1
CN106466485B (zh) 一种具有细胞内吞介导功能的靶向配体-药物偶联体
CN105504063B (zh) 一类防御素-白蛋白的抗肿瘤融合蛋白及其制备和应用
Meng et al. Improved immunocompatibility of active targeting liposomes by attenuating nucleophilic attack of cyclic RGD peptides on complement 3
CN105315350A (zh) 抗肿瘤血管生成多肽mPEG-Mal-Cys-AS16
CN111995686B (zh) 一种具有抗血管生成活性的药物及其制备方法
CN101486758A (zh) mda-7/IL-24突变体多肽及其制备方法及用途
CN102372770A (zh) 一种抑血管生成素、纯化方法及含有它们的药物组合物
CN105985447A (zh) 一种白蛋白结合型肿瘤坏死因子相关凋亡诱导配体变异体及其制备方法和用途
Yuan et al. Smart delivery of poly-peptide composite for effective cancer therapy
Liu et al. In vivo pharmacokinetics, immunogenicity and mechanism of PEGylated antitumor polypeptide
US20240082346A1 (en) Composition Comprising an Antiviral Agent and a CXCR4 Selective Antagonist and Methods For Using the Same
Zhu et al. Functional identification of the C-terminal domain of rhCNB
CN105622721A (zh) 一种聚乙二醇修饰的血管生成抑制剂hs-1及其应用
CN105802946A (zh) 聚乙二醇化的门冬酰胺酶及其应用
CN104558122A (zh) 与整合素受体相关的抗肿瘤多肽及其治疗和诊断用途

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)